If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Raffaele Cozzolongo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles
Ribavirin Medicine & Life Sciences
Interferons Medicine & Life Sciences
Chronic Hepatitis C Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
Virus Diseases Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Genotype Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2019

Effects of some food components on non-alcoholic fatty liver disease severity: Results from a cross-sectional study

Mirizzi, A., Franco, I., Leone, C. M., Bonfiglio, C., Cozzolongo, R., Notarnicola, M., Giannuzzi, V., Tutino, V., De Nunzio, V., Bruno, I., Buongiorno, C., Campanella, A., Deflorio, V., Pascale, A., Procino, F., Sorino, P. & Osella, A. R., Nov 2019, In : Nutrients. 11, 11, 2744.

Research output: Contribution to journalArticle

Open Access
fatty liver
cross-sectional studies
disease severity
Cross-Sectional Studies
Food

Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy

for the CLEO-AIGO PBC study group, Oct 3 2019, In : Scandinavian Journal of Gastroenterology. 54, 10, p. 1274-1282 9 p.

Research output: Contribution to journalArticle

Ursodeoxycholic Acid
Cholangitis
Italy
Paris
Gastroenterology
Eicosapentaenoic Acid
fatty liver
eicosapentaenoic acid
arachidonic acid
Arachidonic Acid

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

ANSWER Study Investigators, Jun 16 2018, In : Lancet (London, England). 391, 10138, p. 2417-2429 13 p.

Research output: Contribution to journalArticle

Albumins
Fibrosis
Therapeutics
Ascites
Pragmatic Clinical Trials

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Caraceni, P., Riggio, O., Angeli, P., Alessandria, C., Neri, S., Foschi, F. G., Levantesi, F., Airoldi, A., Boccia, S., Svegliati-Baroni, G., Fagiuoli, S., Romanelli, R. G., Cozzolongo, R., Di Marco, V., Sangiovanni, V., Morisco, F., Toniutto, P., Tortora, A., De Marco, R., Angelico, M. & 30 others, Cacciola, I., Elia, G., Federico, A., Massironi, S., Guarisco, R., Galioto, A., Ballardini, G., Rendina, M., Nardelli, S., Piano, S., Elia, C., Prestianni, L., Cappa, F. M., Cesarini, L., Simone, L., Pasquale, C., Cavallin, M., Andrealli, A., Fidone, F., Ruggeri, M., Roncadori, A., Baldassarre, M., Tufoni, M., Zaccherini, G., Bernardi, M., Domenicali, M., Giannone, F. A., Auriemma, F., Conte, D. & Salerno, F., 2018, In : The Lancet. 391, 10138, p. 2417-2429

Research output: Contribution to journalArticle

Albumins
Fibrosis
Therapeutics
Ascites
Pragmatic Clinical Trials